Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146513 | 0.84 | DGAT1 (0.44) | DGAT1ALDH1A1KCNN4 | |
| SCHEMBL28378729 | 0.81 | DGAT1 (0.35) | DGAT1ALDH1A1TSHR | |
| SCHEMBL10011069 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL9384058 | 0.78 | DGAT1 (0.34) | DGAT1ALDH1A1 | |
| SCHEMBL23535032 | 0.77 | DGAT1 (0.32) | DGAT1ALDH1A1 | |
| Acetone SCHEMBL1092947 | 0.77 | ALDH1A1 (0.33) | DGAT1ALDH1A1TSHRLMNA | |
| SCHEMBL15065416 | 0.77 | DGAT1 (0.32) | DGAT1ALDH1A1 | |
| SCHEMBL7164418 | 0.75 | DGAT1 (0.46) | DGAT1ALDH1A1KCNN4SRCKEAP1 | |
| SCHEMBL12121537 | 0.75 | DGAT1 (0.46) | DGAT1ALDH1A1KCNN4SRCKEAP1 | |
| SCHEMBL194990 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260109704-A1 | 5-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108510-A1 | PYRAZOLYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108509-A1 | 6-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3617235-B1 | COMPOUND HAVING SUBSTANCE THAT HAS AFFINITY FOR SOLUBLE PROTEIN, CLEAVABLE MOIETY, AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO KK (JP) | 2026-02-18 | — | — | EP | disclosed |
| EP-4603507-A2 | COMPOUND HAVING AFFINITY SUBSTANCE TO SOLUBLE PROTEIN, CLEAVABLE PORTION AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-12384780-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4466269-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-5202321-A | Antihistamine, antiallergens, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1993-04-13 | — | — | US | disclosed |
| EP-0532178-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
| EP-0518426-A1 | Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-12-16 | — | — | EP | disclosed |
| EP-0337260-B1 | PROCESS FOR THE PRODUCTION OF ENOL ETHERS AND THEIR USE IN THE PREPARATION OF ALDEHYDES | BASF Aktiengesellschaft (DE) | 1992-12-02 | — | — | EP | disclosed |
| US-5104882-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-04-14 | — | — | US | disclosed |
| EP-0399818-A1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC. (CA) | 1990-11-28 | — | — | EP | disclosed |
| US-4960954-A | ELIMINATING ALCOHOL FROM ACETAL OR KETAL USING PHOSPHATE OR ZEOLITE CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
| EP-0337260-A1 | Process for the production of enol ethers and their use in the preparation of aldehydes | BASF Aktiengesellschaft (DE) | 1989-10-18 | — | — | EP | disclosed |
| US-4425360-A | Pharmacologically active novel O-substituted pyruvic acid oximes | BOEHRINGER MANNHEIM GMBH (DE) | 1984-01-10 | — | — | US | disclosed |
| US-4304928-A | 2-Alkoxyacrylate process | CHEVRON RESEARCH COMPANY (US) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384780-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | DGAT1 2289/4885ALDH1A1 1913/4885KCNN4 4859/4885 |
| US-20260109704-A1 | 5-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | CGAS, GBA3, CYP11B2 | DGAT1 2730/4885ALDH1A1 1752/4885KCNN4 4268/4885 |
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, PRKG1, GMPS | DGAT1 1730/4885ALDH1A1 1223/4885KCNN4 2998/4885 |
| US-20260108510-A1 | PYRAZOLYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | CGAS, GBA3, CYP11B2 | DGAT1 3385/4885ALDH1A1 1500/4885KCNN4 3678/4885 |
| US-20260108509-A1 | 6-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | CGAS, GBA3, GBA1 | DGAT1 2465/4885ALDH1A1 1475/4885KCNN4 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.